Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471437 | 0.86 | NOS3 (0.46) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL28746485 | 0.85 | L3MBTL1 (0.43) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL13208426 | 0.83 | POLB (0.40) | L3MBTL1ALDH1A1GAAMAPK1HPGD | |
| SCHEMBL15616201 | 0.82 | NUDT1 (0.47) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL677234 | 0.81 | NOS3 (0.52) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL31121348 | 0.81 | NOS3 (0.52) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL22474623 | 0.81 | NOS3 (0.44) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL15464519 | 0.80 | GAA (0.54) | L3MBTL1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL15464119 | 0.80 | IL1B (0.49) | NOS3NOS2L3MBTL1ALDH1A1GAA | |
| SCHEMBL19732851 | 0.79 | NOS3 (0.50) | NOS3NOS2L3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365692-B2 | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | NOVARTIS AG (CH) | 2025-07-22 | — | — | US | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12257243-B2 | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | NOVARTIS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220071972-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-1723156-B1 | PROCESS FOR THE PREPARATION OF PYRIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-7687632-B2 | Process for the preparation of pyridine derivatives | DOW AGROSCIENCES LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070249837-A1 | Process for the Preparation of Pyridine Derivatives | CORTEVA AGRISCIENCE LLC | 2007-10-25 | — | — | US | disclosed |
| EP-1723156-A1 | PROCESS FOR THE PREPARATION OF PYRIDINE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005063780-A1 | PROCESS FOR THE PREPARATION OF PYRIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | COL2A1, COL1A1, HCAR1 | NOS3 1843/4885NOS2 1516/4885L3MBTL1 4188/4885 |
| US-20070249837-A1 | Process for the Preparation of Pyridine Derivatives | CBR1, CBR3, CCNT1 | NOS3 1032/4885NOS2 579/4885L3MBTL1 4535/4885 |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | NOS3 3408/4885NOS2 3699/4885L3MBTL1 1411/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | NOS3 3408/4885NOS2 3699/4885L3MBTL1 1411/4885 |
| US-20220071972-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | COL2A1, COL1A1, FGF1 | NOS3 2591/4885NOS2 2545/4885L3MBTL1 4172/4885 |
| US-12257243-B2 | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | COL2A1, COL1A1, FGF1 | NOS3 2452/4885NOS2 2401/4885L3MBTL1 4239/4885 |
| US-12365692-B2 | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | COL2A1, COL1A1, HCAR1 | NOS3 1843/4885NOS2 1516/4885L3MBTL1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.